Condition (MeSH)
Liver Cirrhosis, Alcoholic
ClinicalTrials.gov lists 43 trials for Liver Cirrhosis, Alcoholic or a narrower condition beneath it. Pharmicell Co., Ltd. has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
43 of the 43 trials are tagged with Liver Cirrhosis, Alcoholic itself; the rest are tagged with a narrower condition beneath it.
When did Liver Cirrhosis, Alcoholic trials start? (21)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2024 | 4 |
| 2023 | 2 |
| 2022 | 3 |
| 2021 | 3 |
| 2020 | 2 |
| 2019 | 4 |
| 2018 | 2 |
| 2017 | 1 |
| 2016 | 2 |
Showing 10 of 21 earlier years.
No forecast is made for this condition: it averages 2.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Liver Cirrhosis, Alcoholic trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 1/2 | 1 |
| Phase 2 | 7 |
| Phase 3 | 2 |
| Phase 4 | 2 |
| Not applicable | 9 |
| Observational | 19 |
How many Liver Cirrhosis, Alcoholic trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 8 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 2 |
| Completed | 15 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Liver Cirrhosis, Alcoholic trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Pharmicell Co., Ltd. | 5 |
Which drugs are being tested for Liver Cirrhosis, Alcoholic? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| ROSUVASTATIN | 1 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| baclofen 2% | 2 |
| Propranolol - Spironolactone | 1 |
| Conventional therapy plus low dose UCMSCs treatment | 1 |
| BLOOD SAMPLES | 1 |
| Low dose losartan | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Liver Cirrhosis, Alcoholic trials report? (4)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Intraoperative cardiac arrest | 3 | 1 |
| Disseminated fungal infection leading to death | 2 | 1 |
| Primary non-function of the liver | 2 | 1 |
| Inferior vena cava thrombus | 1 | 1 |
Which publications cover Liver Cirrhosis, Alcoholic? (123)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Inflammation remains a dynamic component of portal hypertension in regressive alcohol-related cirrhosis. | United European gastroenterology journal | 2025 | Yes |
| Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort. | Journal of hepatology | 2023 | Yes |
| Non-selective beta-blockers increase overall and liver mortality in alcoholic cirrhosis with MELD ≥ 12 over 5 years of follow-up. | Liver international : official journal of the International Association for the Study of the Liver | 2021 | Yes |
| Point shear wave elastography predicts fibrosis severity and steatohepatitis in alcohol-related liver disease. | Hepatology international | 2020 | Yes |
| Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. | Journal of hepatology | 2019 | Yes |
Showing 5 of 123 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.